抗狭心症薬
WordNet
- a substance that exerts some force or effect
- a businessman who buys or sells for another in exchange for a commission (同)factor, broker
- any agent or representative of a federal agency or bureau (同)federal agent
- a representative who acts on behalf of other persons or organizations
- an active and efficient cause; capable of producing a certain effect; "their research uncovered new disease agents"
PrepTutorEJDIC
- 『代理人』;周旋人 / 働き(作用)を起こすもの;作用物,薬剤 / (政府機関,特にFBI,CIAなどの)部員,機関員
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- 1,4-Dihydropyridines: A Class of Pharmacologically Important Molecules.
- Khedkar SA, Auti PB.Author information Department of Pharmaceutical Chemistry, STES's Sinhgad Institute of Pharmacy, Narhe, Pune-41. Maharashtra. India. pratibhaauti@yahoo.com.AbstractThe 1,4-dihydropyridines (DHPs), a class of drugs possess a wide variety of biological and pharmacological actions, have represented one of the most important groups of calcium-channel modulating agents and have experienced widespread use in the treatment of cardiovascular disease which include antihypertensive, antianginal, vasodilator and cardiac depressants activities. It also shows antibacterial, anticancer, antileishmanial, anticoagulant, anticonvulsant, antitubercular, antioxidant, antiulcer, CFTR, antimalarials, neuroprotection properties, HIV-1 protease inhibitors, antifertility activities and many more. There are many marketed drugs which contain 1,4-dihydropyridines ring as basic scaffold. In this review, attempts have been made to disclose various therapeutic applications of 1,4-dihydropyridine derivatives which have been reported during the period of 2001-2011.
- Mini reviews in medicinal chemistry.Mini Rev Med Chem.2013 Nov 19. [Epub ahead of print]
- The 1,4-dihydropyridines (DHPs), a class of drugs possess a wide variety of biological and pharmacological actions, have represented one of the most important groups of calcium-channel modulating agents and have experienced widespread use in the treatment of cardiovascular disease which include anti
- PMID 24251802
- Ranolazine for congenital and acquired late INa-linked arrhythmias: in silico pharmacological screening.
- Moreno JD, Yang PC, Bankston JR, Grandi E, Bers DM, Kass RS, Clancy CE.Author information From the Tri-Institutional MD-PhD Program, Weill Cornell Medical College/The Rockefeller University/Sloan-Kettering Cancer Institute, New York, NY.AbstractRATIONALE: The antianginal ranolazine blocks the human ether-a-go-go-related gene-based current IKr at therapeutic concentrations and causes QT interval prolongation. Thus, ranolazine is contraindicated for patients with preexisting long-QT and those with repolarization abnormalities. However, with its preferential targeting of late INa (INaL), patients with disease resulting from increased INaL from inherited defects (eg, long-QT syndrome type 3 or disease-induced electric remodeling (eg, ischemic heart failure) might be exactly the ones to benefit most from the presumed antiarrhythmic properties of ranolazine.
- Circulation research.Circ Res.2013 Sep 13;113(7):e50-61. doi: 10.1161/CIRCRESAHA.113.301971. Epub 2013 Jul 29.
- RATIONALE: The antianginal ranolazine blocks the human ether-a-go-go-related gene-based current IKr at therapeutic concentrations and causes QT interval prolongation. Thus, ranolazine is contraindicated for patients with preexisting long-QT and those with repolarization abnormalities. However, with
- PMID 23897695
- Pharmacology at work for cardio-oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs.
- Minotti G.Author information CIR and Drug Sciences, University Campus Bio-Medico, Rome, Italy. g.minotti@unicampus.itAbstractAntitumor drugs may cause asymptomatic diastolic dysfunction that introduces a lifetime risk of heart failure or myocardial infarction. Cardio-oncology is the discipline committed to the cardiac surveillance and management of cancer patients and survivors; however, cardio-oncology teams do not always attempt to treat early diastolic dysfunction. Common cardiovascular drugs, such as β blockers or angiotensin-converting enzyme inhibitors or others, would be of uncertain efficacy in diastolic dysfunction. This perspective describes the potential value of ranolazine, an antianginal drug that improves myocardial perfusion by relieving diastolic wall tension and dysfunction. Ranolazine acts by inhibiting the late inward sodium current, and pharmacological reasonings anticipate that antitumor anthracyclines and nonanthracycline chemotherapeutics might well induce anomalous activation of this current. These notions formed the rationale for a clinical study of the efficacy and safety of ranolazine in cancer patients. This study was not designed to demonstrate that ranolazine reduced the lifetime risk of cardiac events; it was designed as a short term proof-of-concept study that probed the following hypotheses: 1) asymptomatic diastolic dysfunction could be detected a few days after patients completed antitumor therapy, and 2) ranolazine was active and safe in relieving echocardiographic and/or biohumoral indices of diastolic dysfunction, measured at 5 weeks or 6 months of ranolazine administration. These facts illustrate the translational value of pharmacology, which goes from identifying therapeutic opportunities to validating hypotheses in clinical settings. Pharmacology is a key to the success of cardio-oncology.
- The Journal of pharmacology and experimental therapeutics.J Pharmacol Exp Ther.2013 Sep;346(3):343-9. doi: 10.1124/jpet.113.204057. Epub 2013 Jul 1.
- Antitumor drugs may cause asymptomatic diastolic dysfunction that introduces a lifetime risk of heart failure or myocardial infarction. Cardio-oncology is the discipline committed to the cardiac surveillance and management of cancer patients and survivors; however, cardio-oncology teams do not alway
- PMID 23818683
Japanese Journal
- Clinically applicable antianginal agents suppress osteoblastic transformation of myogenic cells and heterotopic ossifications in mice
- Journal of bone and mineral metabolism 31(1), 26-33, 2013-01-30
- NAID 10031168834
- 第12回体表心臓微小電位研究会 TWA voltage,自律神経機能および血漿カテコラミンに及ぼす各種抗狭心症薬の比較検討
- Evaluation of Antianginal Agents by Autonomic Nerve Functions, Microvolt T wave-Alternans and Plasma Catecholamine Levels in Patients with Post-Myocardial Infarction
- Circulation journal : official journal of the Japanese Circulation Society 66(Supplement_I), 658, 2002-03-31
- NAID 110002637220
Related Links
- Since this patient had already had a coronary angiogram 4 years before the presentation and no report of a bridge was given, one possibility is that the use of antianginal agents presumably including nitroglycerine might have ...
- Antianginal agents Presentation Transcript 1. Antianginal Agents 2. Antianginal Agents Nitrates Beta blockers Calcium channel blockers 3. Angina Pectoris (Chest Pain) When the supply of ...
Related Pictures
★リンクテーブル★
[★]
- 英
- antianginal agents, antianginal drug
- 関
- 狭心症
種類
硝酸薬
- 冠血管スパズム緩解→酸素供給↑
- 末梢血管拡張→心筋仕事量↓→心筋酸素需要↓
特徴
- 小動脈より静脈を拡張させる → 前負荷の減少
- 冠血管では、細い動脈より太い動脈を弛緩させる
β遮断薬
- 冠血管スパズム緩解→酸素供給↑ (SPC.226)
- 心筋抑制→心筋仕事量↓→心筋酸素需要↓
作用機序
- 電位依存性型Ca2+チャネルのαサブユニットに作用
その他の冠血管拡張薬
抗狭心症薬の使い分け
[★]
- 代行者、代理人。代理業者
- 政府職員、官吏
- ある後位をする人、ある作用をするもの。動員、動力因、作用因。(文法)動作主。科学的変化を起こさせるもの、薬品、~剤。病原体
- 関
- agonist、agonistic、attorney、delegate、drug、etiologic agent、fomes、fomites、mediator、pathogen、pathogenic、pharmaceutical preparation、vector、vehicle